Logo image of ANIX

ANIXA BIOSCIENCES INC (ANIX) Stock Price, Quote, News and Overview

NASDAQ:ANIX - Nasdaq - US03528H1095 - Common Stock - Currency: USD

2.84  -0.08 (-2.74%)

After market: 2.9782 +0.14 (+4.87%)

ANIX Quote, Performance and Key Statistics

ANIXA BIOSCIENCES INC

NASDAQ:ANIX (3/7/2025, 8:05:00 PM)

After market: 2.9782 +0.14 (+4.87%)

2.84

-0.08 (-2.74%)

Sector
GICS SectorHealth Care
GICS IndustryBiotechnology
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS SubIndustryBiotechnology
Statistics
52 Week High4.2
52 Week Low2.07
Market Cap91.45M
Shares32.20M
Float29.87M
Yearly DividendN/A
Dividend YieldN/A
PEN/A
Fwd PEN/A
Earnings (Next)N/A N/A
IPO10-07 1983-10-07


ANIX short term performance overview.The bars show the price performance of ANIX in the last week, last 2 weeks, last month, last 3 and 6 months. 1 week 2 week 1 month 3 months 6 months -2 -4 -6 -8 -10

ANIX long term performance overview.The bars show the price performance of ANIX in the last 1, 2 and 3 years. 1 year 2 years 3 years 0 -10 -20 -30

The current stock price of ANIX is 2.84 USD. In the past month the price decreased by -10.97%. In the past year, price decreased by -12.62%.

ANIXA BIOSCIENCES INC / ANIX Daily stock chart

ANIX Competitors/Peers

The largest stocks on the US markets in the "Biotechnology" sub-industry
Full List
Symbol
Name
TA
FA
PE
Market Cap
ABBV ABBVIE INC 21.17 378.30B
AMGN AMGEN INC 16.39 174.51B
GILD GILEAD SCIENCES INC 25.47 146.22B
VRTX VERTEX PHARMACEUTICALS INC 1683.76 125.39B
REGN REGENERON PHARMACEUTICALS 15.5 77.34B
ARGX ARGENX SE - ADR 231.21 36.10B
ALNY ALNYLAM PHARMACEUTICALS INC N/A 31.66B
ONC BEIGENE LTD-ADR N/A 26.47B
BNTX BIONTECH SE-ADR N/A 26.08B
BIIB BIOGEN INC 9.13 22.01B
NTRA NATERA INC N/A 19.02B
GMAB GENMAB A/S -SP ADR 24.89 15.34B

About ANIX

Company Profile

ANIX logo image Anixa Biosciences, Inc. is a biotechnology company, which engages in the development of therapies and vaccines focused on oncology and infectious disease. The company is headquartered in San Jose, California and currently employs 4 full-time employees. Its segments include CAR-T Therapeutics, Cancer Vaccines, Anti-Viral Therapeutics and Other. Its vaccine programs include the development of a preventative vaccine against triple negative breast cancer (TNBC), the most lethal form of breast cancer, as well as other forms of breast cancer and the development of a preventative vaccine against ovarian cancer. Its therapeutics programs include the development of a chimeric endocrine receptor T cell therapy, a novel form of chimeric antigen receptor T cell (CAR-T) technology, initially focused on treating ovarian cancer, which is being developed by its subsidiary, Certainty Therapeutics, Inc. (Certainty). Certainty is developing immuno-therapy drugs against cancer. The Company’s vaccine portfolio consists of technology focused on the immunization against specific retired proteins.

Company Info

ANIXA BIOSCIENCES INC

3150 Almaden Expy Ste 250

San Jose CALIFORNIA 95118 US

CEO: Amit Kumar

Employees: 5

Company Website: https://www.anixa.com/

Investor Relations: http://www.ir.anixa.com

Phone: 14087089808

ANIXA BIOSCIENCES INC / ANIX FAQ

What is the stock price of ANIXA BIOSCIENCES INC today?

The current stock price of ANIX is 2.84 USD. The price decreased by -2.74% in the last trading session.


What is the ticker symbol for ANIXA BIOSCIENCES INC stock?

The exchange symbol of ANIXA BIOSCIENCES INC is ANIX and it is listed on the Nasdaq exchange.


On which exchange is ANIX stock listed?

ANIX stock is listed on the Nasdaq exchange.


What is the price forecast or stock price prediction for ANIXA BIOSCIENCES INC stock?

8 analysts have analysed ANIX and the average price target is 8.67 USD. This implies a price increase of 205.28% is expected in the next year compared to the current price of 2.84. Check the ANIXA BIOSCIENCES INC stock analysts ratings, price target forecast and up-and down grades for more detailed information.


What is ANIXA BIOSCIENCES INC worth?

ANIXA BIOSCIENCES INC (ANIX) has a market capitalization of 91.45M USD. This makes ANIX a Micro Cap stock.


How many employees does ANIXA BIOSCIENCES INC have?

ANIXA BIOSCIENCES INC (ANIX) currently has 5 employees.


What are the support and resistance levels for ANIXA BIOSCIENCES INC (ANIX) stock?

ANIXA BIOSCIENCES INC (ANIX) has a support level at 2.83 and a resistance level at 3.02. Check the full technical report for a detailed analysis of ANIX support and resistance levels.


Should I buy ANIXA BIOSCIENCES INC (ANIX) stock?

There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:


Does ANIXA BIOSCIENCES INC (ANIX) stock pay dividends?

ANIX does not pay a dividend.


What is the Price/Earnings (PE) ratio of ANIXA BIOSCIENCES INC (ANIX)?

ANIXA BIOSCIENCES INC (ANIX) does not have a PE ratio as the earnings reported over the last twelve months were negative (-0.39).


What is the Short Interest ratio of ANIXA BIOSCIENCES INC (ANIX) stock?

The outstanding short interest for ANIXA BIOSCIENCES INC (ANIX) is 1.35% of its float. Check the ownership tab for more information on the ANIX short interest.


ANIX Technical Analysis

ChartMill assigns a technical rating of 3 / 10 to ANIX. When comparing the yearly performance of all stocks, ANIX is a bad performer in the overall market: 73.66% of all stocks are doing better.


Chartmill TA Rating
Chartmill Setup Rating

ANIX Fundamental Analysis

ChartMill assigns a fundamental rating of 3 / 10 to ANIX. ANIX has a great financial health rating, but its profitability evaluates not so good.


Chartmill FA Analysis
Valuation
Growth
Profitability
Health
Dividend

ANIX Financial Highlights

Over the last trailing twelve months ANIX reported a non-GAAP Earnings per Share(EPS) of -0.39. The EPS decreased by -21.88% compared to the year before.


Industry RankSector Rank
PM (TTM) N/A
ROA -58.14%
ROE -62.78%
Debt/Equity 0
Chartmill High Growth Momentum
EPS Q2Q%0%
Sales Q2Q%N/A
EPS 1Y (TTM)-21.88%
Revenue 1Y (TTM)-100%

ANIX Ownership and Analysts

ChartMill assigns a Buy % Consensus number of 83% to ANIX. The Buy consensus is the average rating of analysts ratings from 8 analysts.


Ownership
Inst Owners16.41%
Ins Owners2.39%
Short Float %1.35%
Short Ratio3.22
Analysts
Analysts82.5
Price Target8.67 (205.28%)
EPS Next Y11.08%
Revenue Next YearN/A